$19.48 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of June 2023 : $3.51 B

According to BeiGene 's latest financial reports the company has $3.51 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2023)

Cash on Hand by year

Year Cash on Hand Change
2022-12-31$4.54 B-31.47%
2021-12-31$6.62 B42.2%
2020-12-31$4.65 B372.73%
2019-12-31$0.98 B-45.53%
2018-12-31$1.80 B116.02%
2017-12-31$0.83 B127.48%
2016-12-31$0.36 B266.39%
2015-12-31$0.10 B126.35%
2014-12-31$44.39 M1030.79%
2013-12-31$3.92 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
$0.10 B-96.93%๐Ÿ‡บ๐Ÿ‡ธ USA
$29.72 M-99.15%๐Ÿ‡บ๐Ÿ‡ธ USA